FPC members,
Some more new science to engage your minds. First, producing an individualized organoid to test treatments against and to predict treatment success in prostate cancer. Personalized medicine/ Targeted therapy is coming:
sciencedaily.com/releases/2...
Second, new nanoprobes detect cancer more precisely than previously and can be used to identify treatment sites:
sciencedaily.com/releases/2...
Third, new organelle discovered that plays a significant role in bone metastasis in breast and prostate cancers. The role of the gene DACT1 in allowing metastasis to happen.
sciencedaily.com/releases/2...
Lastly, the future of immunotherapy in off-the-shelf treatments. The development of neoantigen therapies that could be removed from a shelf and given to engage the immune system. The post I wrote on Advaxis discussed their new vaccine program using multiple neoantigens to achieve a significant immune response against prostate cancer. From the article:
Weidanz said immunotherapy holds the promise of transforming cancer into a more manageable condition with better prognoses for patients.
"We are getting to a point where we will be able to make cancer more of a chronic disease," Weidanz said. "Now, we look at five-year survival. Maybe we can start looking at 15- or 20-year survival readouts because we're able to manage the disease with immunotherapies that are being developed. It's a very exciting time."
sciencedaily.com/releases/2...
Keeping an eye on the science....
Don Pescado